Loading clinical trials...
Loading clinical trials...
The study is designed to evaluate the clinical efficacy, safety and tolerability of selumetinib with radioactive iodine therapy in patients with differentiated thyroid cancer.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AstraZeneca
NCT06671184 · Differentiated Thyroid Cancer
NCT07436455 · Thyroid Cancer, Differentiated Thyroid Cancer
NCT07287748 · DTC - Differentiated Thyroid Cancer
NCT05024929 · Papillary Thyroid Cancer, Pediatric Cancer, and more
NCT06970353 · Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation, Advanced PDTC or ATC With NRAS Mutation
Research Site
Birmingham, Alabama
Research Site
Little Rock, Arkansas
Research Site
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions